+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

  • ID: 4850658
  • Report
  • August 2019
  • Region: Global
  • 212 pages
  • GlobalData

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Endo Pharmaceuticals
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer
  • MORE
Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

Summary

The prostate cancer market will undergo a moderate increase at a compound annual growth rate (CAGR) of 3.3% from an estimated $9.3bn in 2018 to $12.8bn in 2028 in the eight major markets (8MM - US, France, Germany, Italy, Spain, UK, Japan and China. The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone naïve (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide).

Of these, the biggest driver of growth is the expansion of second-generation hormonal agents into metastatic hormone-naive prostate cancer (mHNPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), which will bring these expensive drugs into earlier lines of therapy.

This will doubly impact market growth, as the shifting paradigm will create space in the metastatic castration-resistant prostate cancer (mCRPC) space, where these agents once reigned, allowing pipeline agents a chance to gain substantial market share and fill this void.

Second-generation hormonal therapies Johnson & Johnson’s Zytiga (abiraterone acetate) and Erleada (apalutamide), Astellas/Pfizer’s Xtandi (enzalutamide) and Bayer/Orion’s Nubeqa (darolutamide) have been racing to acquire approvals and label expansions over the past couple years.

Between 2018 and 2019, three of these agents gained approval in nmCRPC. Zytiga gained a label expansion for metastatic hormone-naive prostate cancer (mHNPC) in 2017 for the EU and in 2018 for the US, while the other three agents are soon to follow. J&J filed for US Food and Drug Administration (FDA) approval of Erleada in mHNPC in April 2019, and Xtandi was given an FDA priority review in August.

The report “Prostate Cancer: Global Drug Forecast and Market Analysis to 2028” provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

Scope
  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global prostate cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global prostate cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • AstraZeneca
  • Endo Pharmaceuticals
  • GlaxoSmithKline
  • Merck & Co.
  • Pfizer
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Prostate Cancer: Executive Summary
2.1 Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry
2.2 Big Pharma Brands Enter the Prostate Cancer Market Using Combination Strategies for mCRPC
2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response
2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine
2.5 What Do the Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods, Population
5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer
5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category
5.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis
5.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
5.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status
5.5 Epidemiological Forecast for Prostate Cancer (2018-2028)
5.5.1 Diagnosed Incident Cases of Prostate Cancer
5.5.2 Age-Specific Incident Cases of Prostate Cancer
5.5.3 Diagnosed Incident Cases of Prostate Cancer by Gleason Score
5.5.4 Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of Prostate Cancer by Risk Category
5.5.6 Metastatic Cases at Diagnosis
5.5.7 Five-Year Diagnosed Prevalent Cases of Prostate Cancer
5.5.8 Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 France
6.5 Germany
6.6 Italy
6.7 Spain
6.8 UK
6.9 Japan
6.10 China

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Therapies with a Durable OS Benefit or Cure for mCRPC
8.3 Identification of New Targets and Positive Predictive Biomarkers of Response
8.4 Advancements in the Detection and Treatment of Drug Resistance
8.5 Therapeutic Options for nmCRPC

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Johnson & Johnson
10.3.2 Astellas
10.3.3 AstraZeneca
10.3.4 Bayer
10.3.5 Clovis Oncology
10.3.6 Merck
10.3.7 Novartis
10.3.8 Pfizer
10.3.9 Roche
10.3.10 Sanofi

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 China (Urban)
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers

12 Appendix

List of Tables
Table 1: Prostate Cancer: Key Metrics in Eight Major Pharmaceutical Markets
Table 2: Stage Definitions for PCa
Table 3: NCCN Risk-Category Classification System for PCa
Table 4: Risk Factors and Comorbidities for Prostate Cancer
Table 5: AJCC Staging of Prostate Cancer
Table 6: Treatment Guidelines for Prostate Cancer
Table 7: Country Profile - US
Table 8: Country Profile - France
Table 9: Country Profile - Germany
Table 10: Country Profile - Italy
Table 11: Country Profile - Spain
Table 12: Country Profile - UK
Table 13: Country Profile - Japan
Table 14: Country Profile - China
Table 15: Leading Branded Treatment for PCa, 2019
Table 16: Key Companies in the PCa Market in the 8MM, 2018-2028
Table 17: J&J’s PCa Portfolio Assessment, 2019
Table 18: Astellas’ PCa Portfolio Assessment, 2019
Table 19: AstraZeneca’s PCa Portfolio Assessment, 2019
Table 20: Bayer’s PCa Portfolio Assessment, 2019
Table 21: Clovis Oncology’s PCa Portfolio Assessment, 2019
Table 22: Merck’s PCa Portfolio Assessment, 2019
Table 23: Novartis’ PCa Portfolio Assessment, 2019
Table 24: Pfizer’s PCa Portfolio Assessment, 2019
Table 25: Roche’s PCa Portfolio Assessment, 2019
Table 26: Sanofi’s PCa Portfolio Assessment, 2019
Table 27: Prostate Cancer Market - Global Drivers and Barriers, 2018-2028
Table 28: Key Events Impacting Sales for Prostate Cancer in the US, 2018-2028
Table 29: Prostate Cancer Market -Drivers and Barriers in the US, 2018-2028
Table 30: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2018-2028
Table 31: Prostate Cancer Market - Drivers and Barriers in the 5EU, 2018-2028
Table 32: Prostate Cancer Market in the 5EU - Country-Specific Barriers in the 5EU, 2018-2028
Table 33: Key Events Impacting Sales for Prostate Cancer in Japan, 2018-2028
Table 34: Prostate Cancer Market - Drivers and Barriers in Japan, 2018-2028
Table 35: Key Events Impacting Sales for Prostate Cancer in China, 2018-2028
Table 36: Prostate Cancer Market - Drivers and Barriers in China, 2018-2028
Table 37: Key Historical and Projected Launch Dates for Prostate Cancer
Table 38: Key Projected Patent Expiry/Market Exclusivity Dates for Prostate Cancer
Table 39: Average Body BSA Across the 8MM
Table 40: High-Prescribing Physicians (non-KOLs) Surveyed, by Country and Specialty

List of Figures
Figure 1: Global Sales Forecast by Country for Prostate Cancer in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in Prostate Cancer During the Forecast Period, 2018-2028
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents in Prostate Cancer, 2018-2028
Figure 4: 8MM, Diagnosed Incidence of Prostate Cancer, Men, Ages ≥30 Years, 2008-2028
Figure 5: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer
Figure 6: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores
Figure 7: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis
Figure 8: 8MM, Sources Used, Diagnosed Incident Cases of Prostate Cancer by Risk Category
Figure 9: 8MM, Sources Used, Metastatic Cases at Diagnosis
Figure 10: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer
Figure 11: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC
Figure 12: 8MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Prostate Cancer by Progression from Hormone-Sensitive Disease to CRPC by Status
Figure 13: 8MM, Diagnosed Incident Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018
Figure 14: 8MM, Age-Specific Diagnosed Incident Cases of Prostate Cancer, Men, N, 2018
Figure 15: 8MM, Diagnosed Incident Cases of Prostate Cancer by Gleason Score, Ages ≥30 Years, Men, N, 2018
Figure 16: 8MM, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis, Ages ≥30 Years, Men, N, 2018
Figure 17: 8MM, Diagnosed Incident Cases of Prostate Cancer by Risk Category, Ages ≥30 Years, Men, N, 2018
Figure 18: 8MM, Metastatic Cases at Diagnosis, Ages ≥30 Years, Men, N, 2018
Figure 19: 8MM, Five-Year Diagnosed Prevalent Cases of Prostate Cancer, Ages ≥30 Years, Men, N, 2018
Figure 20: 8MM, Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status, Ages ≥30 Years, Men, N, 2018
Figure 21: Treatment Algorithm for Localized Prostate Cancer
Figure 22: Treatment Algorithm for Progressive and Advanced Prostate Cancer
Figure 23: Overview of the Unmet Need and Opportunity in Prostate Cancer, 2019
Figure 24: Overview of the Development Pipeline in PCa
Figure 25: Pivotal Phase II/III Trials for the Promising PCa Pipeline Agents
Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of PCa During the Forecast Period
Figure 27: Analysis of the Company Portfolio Gap in PCa During the Forecast Period
Figure 28: Global (8MM) Sales Forecast by Country for Prostate Cancer in 2018 and 2028
Figure 29: Global (8MM) Sales Forecast by Drug Class for Prostate Cancer in 2018 and 2028
Figure 30: Sales Forecast by Class for Prostate Cancer in the US in 2018 and 2028
Figure 31: Sales Forecast by Class for Prostate Cancer in the 5EU in 2018 and 2028
Figure 32: Sales Forecast by Class for Prostate Cancer in Japan in 2018 and 2028
Figure 33: Sales Forecast by Class for Prostate Cancer in China in 2018 and 2028
Note: Product cover images may vary from those shown
  • AbbVie
  • Advanced Accelerator Applications
  • Advantagene
  • Allergan
  • Astellas
  • AstraZeneca
  • Bayer
  • Clovis Oncology
  • Dendreon
  • Endo Pharmaceuticals
  • Endocyte
  • Ferring Pharmaceuticals
  • Genzyme
  • GlaxoSmithKline
  • Hinova
  • Ipsen
  • Janssen/J&J
  • Merck & Co.
  • Myovant Sciences
  • Novartis
  • Orion
  • Pfizer
  • Roche
  • Sanofi
  • Sotio
  • Takeda
  • TerSera Therapeutics
  • Tesaro
  • Tolmar
Note: Product cover images may vary from those shown
Adroll
adroll